2022 Media Kit

Anti-Cancer Drugs

Media Kit

Download rates, dates, and contact information for advertising, recruitment and content solutions.

Download Kit

  • 69 Total Subscribers
  • 288,165 Oncology Specialty Average Monthly Visits

Website

http://www.anti-cancerdrugs.com/

Audience

Oncologists, cell biologists, immunologists, and pharmacologists

Content Focus

Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy.

Editor-in-Chief

Mels Sluyser, PhD

Frequency

10 / year

Advertising Guidelines

Subject to approval by Editor. New copy must be received by the Publisher two weeks before closing date.